Ane Etxart

Dr. Ane Etxart

Department of Surgery, Biodonostia Health Research Institute, Donostia University Hospital, San Sebastián, Spain
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KGKoldo Garcia-Etxebarria
Koldo Garcia-Etxebarria
AEAne Etxart
Ane Etxart
MBMaialen Barrero
Maialen Barrero
BNBeatriz nafria-jimenez
Beatriz nafria-jimenez
NMNerea Miren Segues Merino
Nerea Miren Segues Merino
Luis BujandaLuis Bujanda
Luis Bujanda
Although the genetic contribution to colorectal cancer (CRC) has been studied in various populations, studies on the applicability of available genetic information in the Basque population are scarce. In total, 835 CRC cases and 940 controls from the Basque population were genotyped and genome-wide association studies were carried out. Mendelian Randomization analyses were used to discover the effect of modifiable risk factors and microbiota on CRC. In total, 25 polygenic risk score models were evaluated to assess their performance in CRC risk calculation. Moreover, 492 inflammatory bowel disease cases were used to assess whether that genetic information would not confuse both conditions. Five suggestive (p < 5 × 10−6) loci were associated with CRC risk, where genes previously associated with CRC were located (e.g., ABCA12, ATIC or ERBB4). Moreover, the analyses of CRC locations detected additional genes consistent with the biology of CRC. The possible contribution of cholesterol, BMI, Firmicutes and Cyanobacteria to CRC risk was detected by Mendelian Randomization. Finally, although polygenic risk score models showed variable performance, the best model performed correctly regardless of the location and did not misclassify inflammatory bowel disease cases. Our results are consistent with CRC biology and genetic risk models and could be applied to assess CRC risk in the Basque population.

20 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LCLoretta De Chiara
Loretta De Chiara
LBLeticia Barcia-Castro
Leticia Barcia-Castro
MGMaría Gallardo-Gómez
María Gallardo-Gómez
MCMaría Páez De La Cadena
María Páez De La Cadena
VMVicenta S. Martínez-Zorzano
Vicenta S. Martínez-Zorzano
OCOscar Cordero
Oscar Cordero
Fecal hemoglobin immunodetection (FIT) in combination with endoscopy has been implemented to reduce mortality from colorectal cancer (CRC), although there are issues that can be improved in relation to participation rates. We studied whether the blood biomarker soluble-CD26 (sCD26), related at least in part to the immune system and inflammation, and/or its dipeptidyl peptidase enzyme activity (DPP4), could help reduce false positives. In a cohort of 1703 individuals who underwent colonoscopy and had a serum sample, sCD26 and DPP4 activity showed statistically significant differences regarding sex and age. According to the colonoscopy findings, sCD26 and DPP4 activity progressively decreased in advanced adenomas and CRC, with statistically significant differences, even between both groups; 918 of them had a FIT result (n = 596 positive cases) with approximately 70% of these (n = 412) false positives. With cut-offs of 440 ng/mL for sCD26, 42 mU/mL for DPP4, and 11 ng/mU for their ratio, the combined information of the three biomarkers (at least positive for one biomarker) identified almost all advanced adenomas and CRC cases in the FIT cohort with approximately half of the false positives compared to FIT. A sequential testing strategy with FIT and our blood biomarker test is proposed.


30 September 2020 in Cirugía Española
Verified
Journal Article
Closed access
IAIgnacio Aguirre-Allende
Ignacio Aguirre-Allende
JEJosé M. Enríquez-Navascués
José M. Enríquez-Navascués
GEGarazi Elorza-Echaniz
Garazi Elorza-Echaniz
AEAne Etxart
Ane Etxart
NBNerea Borda-Arrizabalaga
Nerea Borda-Arrizabalaga
CPCarlos Placer-Galan
Carlos Placer-Galan

22 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KGKoldo Garcia-Etxebarria
Koldo Garcia-Etxebarria
AEAne Etxart
Ane Etxart
MBMaialen Barrero
Maialen Barrero
BNBeatriz nafria-jimenez
Beatriz nafria-jimenez
NMNerea Miren Segues Merino
Nerea Miren Segues Merino
Luis BujandaLuis Bujanda
Luis Bujanda
Background: Some genetic polymorphisms (SNPs) have been proposed as predictors for different colorectal cancer (CRC) outcomes. This work aims to assess their performance in our cohort and find new SNPs associated with them. Methods: A total of 833 CRC cases were analyzed for seven outcomes, including the use of chemotherapy, and stratified by tumor location and stage. The performance of 63 SNPs was assessed using a generalized linear model and area under the receiver operating characteristic curve, and local SNPs were detected using logistic regressions. Results: In total 26 of the SNPs showed an AUC > 0.6 and a significant association (p < 0.05) with one or more outcomes. However, clinical variables outperformed some of them, and the combination of genetic and clinical data showed better performance. In addition, 49 suggestive (p < 5 × 10−6) SNPs associated with one or more CRC outcomes were detected, and those SNPs were located at or near genes involved in biological mechanisms associated with CRC. Conclusions: Some SNPs with clinical data can be used in our population as predictors of some CRC outcomes, and the local SNPs detected in our study could be feasible markers that need further validation as predictors.

16 July 2022 in Cirugía Española
Verified
Journal Article
Closed access
YAYolanda Saralegui Ansorena
Yolanda Saralegui Ansorena
JEJosé M. Enríquez-Navascués
José M. Enríquez-Navascués
CGCarlos Placer Galan
Carlos Placer Galan
NANerea Borda Arrizabalaga
Nerea Borda Arrizabalaga
JAJose Luis Elosegui Aguirrezabala
Jose Luis Elosegui Aguirrezabala
IAIgnacio Aguirre Allende
Ignacio Aguirre Allende